Drug Type Drug conjugates |
Synonyms |
Target |
Action inhibitors, antagonists |
Mechanism CD14 inhibitors(Monocyte differentiation antigen CD14 inhibitors), MAdCAM-1 inhibitors(Mucosal addressin cell adhesion molecule-1 inhibitors), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseClinical |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Sepsis | Preclinical | United States | 19 Jan 2024 | |
| Crohn Disease | Preclinical | United States | - | |
| Psoriasis | Preclinical | United States | - | |
| Rheumatoid Arthritis | Preclinical | United States | - |





